北京商报讯（记者 丁宁）2月13日晚间，三生国健（688336）发布公告称，公司近日获悉，公司的抗 IL-17A人源化单克隆抗体安沐奇塔单抗注射液（商品名：益赛拓）的新药上市申请已经获得国家药品监 督管理局批准，用于治疗适合系统治疗或光疗的中度至重度斑块状银屑病成人患者。 三生国健表示，安沐奇塔单抗获批上市，将进一步丰富公司自免商业化产品管线，提升公司的市场竞争 力，对公司的经营发展具有积极作用。 ...

Core Viewpoint - Recent developments for Fuyuan Pharmaceutical (601089) include participation in national centralized procurement and the approval of a new drug, which are expected to stabilize market share and enhance product offerings [1] Group 1: Key Events - On February 11, the company announced that several of its drugs, including Ezetimibe tablets, are set to be included in the national centralized procurement agreement, with implementation expected by the end of March [1] - On February 10, the company's wholly-owned subsidiary received a drug registration certificate for Ambroxol Hydrochloride Oral Solution, indicating successful consistency evaluation and expanding the product line [1] Group 2: Stock Performance - The stock has shown a downward trend, closing at 25.42 yuan on February 13, down 2.79% for the day and a total decline of 4.44% over the past five days [1] - Trading volume increased to 89.02 million yuan with a turnover rate of 0.72%, while there was a net outflow of 7.75 million yuan in main funds on February 13 [1] - The pharmaceutical and biotechnology sector experienced a decline of 1.06%, with the company's performance lagging behind the industry [1] Group 3: Institutional Insights - Institutional interest remains high, with Tongyuan Investment conducting research on February 9 to understand the progress of innovative drug development, particularly the Phase I clinical results of FY101 injection meeting expectations [1] - The current average target price set by institutions is 31.00 yuan, indicating potential upside from the current price [1] - Revenue growth is projected at 10.94% for 2026, although short-term performance is under pressure, with a forecasted net profit decline of 4.84% for 2025 [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at HKD 3.79, with a transaction volume of HKD 6.119 million, following the announcement of FDA approval for its eye drop product [1] Group 1: FDA Approval and Product Details - Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, has received FDA approval for the commercialization of Carbachol and Bromonidine Tartrate Eye Drops (2.75%/0.1%) [1] - The eye drop, known as BRIMOCHOL PF during clinical trials, will be marketed in the U.S. under the name YUVEZZI, aimed at treating presbyopia [1] Group 2: Commercial Strategy and Partnerships - The FDA approval is considered a strong catalyst for Zhaoke Ophthalmology as it formulates its commercialization strategy [1] - The company has established a partnership network for BRIMOCHOL PF, which currently includes eight commercial partners across the Asia-Pacific region (including South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan/Hong Kong/Macau, Singapore, and Vietnam) and the Middle East [1] - With FDA recognition, Zhaoke anticipates accelerating the market launch of the drug, marking a significant global milestone [1]

Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) shares surged over 32% to $9.33 following FDA approval of its new drug Nereus, aimed at preventing exercise-induced vomiting [1] Group 1: FDA Approval and Drug Details - The FDA approval of Nereus is based on results from three clinical studies comparing the drug group to a placebo group to assess vomiting occurrences [1] - Data indicates that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [1] Group 2: Market Implications - The approval is expected to provide a new commercialization growth point for the company and enhance its product portfolio in the central nervous system and related indications [1]

Core Viewpoint - The approval of two supplemental new drug applications for Selinexor (希维奥) by the Hong Kong Department of Health marks a significant expansion for the company in the Hong Kong market, enhancing its competitiveness in the biopharmaceutical industry [1] Group 1: Company Developments - The stock price of Dechra Pharmaceuticals-B (德琪医药-B) increased by approximately 6%, reaching HKD 4.34, with a trading volume of HKD 9.4944 million [1] - The approved applications are for the treatment of multiple myeloma (in combination with bortezomib and dexamethasone for adult patients who have received at least one prior therapy) and relapsed or refractory diffuse large B-cell lymphoma (as a monotherapy for adults who have undergone at least two lines of systemic therapy and are not eligible for hematopoietic stem cell transplantation) [1] Group 2: Industry Implications - The approval signifies the company's ongoing enhancement in research and market promotion capabilities within the biopharmaceutical sector [1] - The introduction of Selinexor is expected to meet the treatment needs for relevant diseases in the Hong Kong market, thereby improving the company's competitive position in the biotechnology industry [1]

Core Viewpoint - Jichuan Pharmaceutical's subsidiary has received approval for a new drug, which is expected to positively impact the company's future development [1] Group 1: Drug Approval - Jichuan Pharmaceutical announced that its wholly-owned subsidiary, Jichuan Limited, has received a drug registration certificate from the National Medical Products Administration for the drug Marcilosavir Tablets [1] - The drug is classified as a Class 1 new drug and is a next-generation polymerase acidic protein (PA) nuclease inhibitor with broad-spectrum antiviral properties against influenza viruses [1] - The approved indication is for the treatment of previously healthy adults with uncomplicated influenza A and B [1] Group 2: Market Development and Uncertainties - The approval of this cooperative product is expected to have a positive effect on the company's future development [1] - However, the drug's market launch will require a development cycle and is subject to uncertainties influenced by pharmaceutical industry policies and procurement bidding [1]